Theme watch · accelerating
oncology and immunology stocks to watch · July 2026
As of 2026-07-15
Phase 3 depression win for DT120 already ran +60% in public; a seven-shop $50–$74 target band and a $700M raise at $34 are digested, not fresh.…
Post-2026-06-23 reverse merger into Serapha Bio, this stopped being an oncology stock. The tradable object is a defined ~$44–48M pre-close cash…
De-risked Wilson-disease NDA but RSI 88.8 thin-float (6.7M) blowoff into EAN sell-the-news; squeeze-cap, no chase at the vertical.
AbbVie's confirmed $135.11 all-cash takeout (announced 2026-06-23, ~$10.9B, ~49% premium to the $90.38 pre-bid close) caps the stock at the bid…
Best-in-class pan-RAS efficacy (ERAS-0015: 62–75% NSCLC ORR) already discounted through a ~48% post-print crash; stock round-tripped from ~$10 to…
Phase-3-positive, NEJM-published B-cell modulator obexelimab (56% IgG4-RD flare cut) with a BLA filed Q2 2026 into a no-approved-therapy…
Obefazimod's positive Phase 3 UC maintenance data (June 29) completed a de-risked oral pivotal package, but the binary has already fired: a +36%…
Bexobrutideg BTK-degrader franchise is re-rating: six firms raised targets to $32-40 on 2026-07-10, one day after a 44% Q2 revenue miss the…
Best-in-class oral TYK2 narrative accelerating after Phase 3 psoriasis wins (PASI 100 ~40% at Week 24); the Q3 2026 LUMUS Phase 2b lupus topline…
Post-LOTUS de-risked anti–IL-1β (abdakibart) story: the May 5 Phase 2 HS win (HiSCR75 ~42% vs 26% placebo) already re-rated the stock ~4x, and it…
Re-rated ~3x off the $5.68 low as the CD19 T-cell-engager-in-autoimmune narrative accelerated; CLN-978 remissions in lupus/RA (Immunology Day…
Single-asset complement biotech (claseprubart/DNTH103) broke out to a new 52-week high near $102 in July, reclaiming and extending well above the…
Molecular-glue degrader story accelerating: Novartis-validated platform ($150M upfront, $2.1B milestones) plus a wholly-owned NLRP3/NEK7 asset…
Menin-inhibitor commercial ramp accelerating: Revuforj + Niktimvo franchise cleared $100M/quarter with revenue +224% YoY, and the leg being bought…
"3-mo price move" is the stock's market price change, not an orbyd return.
How this page is built
These are the names orbyd covers in the oncology and immunology stocks cluster — each with a dated research dossier. Names currently on the move rank first by 3-month price momentum, then the rest of the covered roster. Cluster membership is assigned by a frontier model, currently read as accelerating.
NRIX drew a cluster of raises (Mizuho/Truist/RBC/Stifel to $33-40), ERAS mapping pivotal cancer trials (raised $500M), ORIC starting Ph3 mCRPC, ABVX Overweight $175. KYMR RBC downgrade is one crack in an otherwise accelerating group.
Questions
- What oncology and immunology stocks does orbyd cover?
- As of 2026-07-15, the oncology and immunology stocks orbyd tracks are led by DFTX, BOLD, MNPR, APGE, each with a dated research dossier. Names already moving rank first by 3-month price momentum; this is research, not a recommendation.
- Is the oncology and immunology stocks theme accelerating or slowing?
- orbyd's model reads this cluster as accelerating as of 2026-07-15. NRIX drew a cluster of raises (Mizuho/Truist/RBC/Stifel to $33-40), ERAS mapping pivotal cancer trials (raised $500M), ORIC starting Ph3 mCRPC, ABVX Overweight $175. KYMR RBC downgrade is one crack in an otherwise accelerating group.
- How does orbyd rank oncology and immunology stocks?
- Every name links to its dated research dossier. Those currently on the move rank first by cross-sectional 3-month price momentum, then the rest of the covered roster by conviction. Methodology is open; this is research, not advice.
Related
As of 2026-07-15 · research, not advice.